Buy & Sell Vanguard Total International Stock Index Fund ETF (VXUS) – Vanguard Total International Stock Index Fund ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Sector/ThematicSector
- -5.67%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 30 daysTypical Hold Time
Over the past 52 weeks, Vanguard Total International Stock Index Fund ETF has traded between a low of $66.61 and a high of $86.96, highlighting its annual price range. Over the past three months, Vanguard Total International Stock Index Fund ETF has recorded a drawdown of -5.67%, reflecting recent price volatility. On average, investors hold Vanguard Total International Stock Index Fund ETF for approximately 30 days, indicating typical investor behavior on the platform.
About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
